These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model. Dey B; Yang YG; Preffer F; Shimizu A; Swenson K; Dombkowski D; Sykes M Transplantation; 1999 Jul; 68(1):141-9. PubMed ID: 10428282 [TBL] [Abstract][Full Text] [Related]
17. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270 [TBL] [Abstract][Full Text] [Related]
18. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Whitaker-Menezes D; Jones SC; Friedman TM; Korngold R; Murphy GF Biol Blood Marrow Transplant; 2003 Sep; 9(9):559-70. PubMed ID: 14506658 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. Drobyski WR; Majewski D; Ozker K; Hanson G J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263 [TBL] [Abstract][Full Text] [Related]
20. Unconventional NK1.1(-) intermediate TCR cells as major T lymphocytes expanding in chronic graft-versus-host disease. Miyakawa R; Miyaji C; Watanabe H; Yokoyama H; Tsukada C; Asakura H; Abo T Eur J Immunol; 2002 Sep; 32(9):2521-31. PubMed ID: 12207336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]